Treatment with Arbutus Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress
Arbutus Pharmaceuticals, a leading biopharmaceutical company focused on discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B virus (HBV) infection, announced that their investigational RNAi therapeutic, Arbutus Imdusiran, in combination with VTP-300, has achieved statistical significance in lowering hepatitis B surface antigen (HBsAg) levels.
The groundbreaking data presented at the European Association for the Study of the Liver (EASL) Congress proved the potential effectiveness of Arbutus’ combination therapy in treating chronic HBV infection. HBsAg is a key biomarker used to evaluate the efficacy of antiviral therapies in patients with chronic HBV.
The Phase 2a clinical trial evaluated the safety and efficacy of Arbutus Imdusiran in combination with VTP-300, a novel nucleoside reverse transcriptase inhibitor. The trial enrolled a significant number of patients with chronic HBV infection, and the results revealed a notable reduction in HBsAg levels. This reduction is encouraging as it suggests a potential strategy for achieving functional cure in patients with chronic HBV.
Arbutus Pharmaceuticals has been at the forefront of developing innovative therapies for chronic HBV, and this latest achievement showcases their commitment to revolutionizing the treatment landscape for this debilitating disease. By leveraging the power of RNA interference (RNAi) technology in combination with VTP-300, Arbutus is paving the way for a potential breakthrough in HBV therapeutics.
The achievement of statistical significance in lowering HBsAg levels with Arbutus Imdusiran and VTP-300 is a significant milestone in our pursuit of a functional cure for chronic HBV infection, said Dr. William T. Symonds, Chief Scientific Officer at Arbutus Pharmaceuticals. We are excited about the potential of this combination therapy to address the unmet medical needs of patients suffering from this chronic infection.
In addition to this positive clinical trial data, Arbutus Pharmaceuticals has previously announced its 2024 Corporate s and provided a financial update. The company aims to further advance the development of Arbutus Imdusiran as a cornerstone therapy in combination with other compounds. This strategic approach is expected to provide more comprehensive treatment options to patients with chronic HBV infection.
Arbutus Pharmaceuticals is committed to conducting further studies to gather additional data from the ongoing Phase 2a clinical trials evaluating imdusiran as a cornerstone therapy. These trials aim to demonstrate the potential of imdusiran in combination with other compounds and are expected to generate more valuable insights into the efficacy and safety of this innovative therapeutic approach. The company anticipates announcing the additional data from these trials in 2024.
The groundbreaking achievements in reducing HBsAg levels bring hope to the millions of people living with chronic HBV infection. The potential for a functional cure presents a promising prospect for patients who have long awaited an effective treatment option. Arbutus Pharmaceuticals continues to demonstrate their dedication to advancing the field of HBV therapeutics and brings us closer to the ultimate goal of eradicating this global health burden.
Comments